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Backgroud: Bone tissue engineering is a new approach for the repair of orbital defects. The aim of the present
study was to explore the feasibility of tissue-engineered bone constructed using bone marrow stromal cells (BMSCs)
that were rapidly isolated and concentrated from bone marrow (BM) by the red cell lysis method, then combined
with β-tricalcium phosphate (β-TCP) to create grafts used to restore orbital bone defects in canines.
Methods: In the experimental group, grafts were constructed using BMSCs obtained by red cell lysis from 20 ml
bone marrow, combined with β-TCP and BM via the custom-made stem cell-scaffold device, then used to repair 10
mm diameter medial orbital wall bony defects in canines. Results were compared with those in groups grafted with
BM/β-TCP or β-TCP alone, or with defects left untreated as controls. The enrichment of BMSCs and nucleated cells
(NCs) in the graft was calculated from the number in untreated bone marrow and in suspensions after red cell lysis.
Spiral computed tomography (CT) scans were performed 1, 4, 12 and 24 weeks after implantation in all groups.
Gross examination, micro-CT and histological measurements were performed 24 weeks after surgery. The results
were analyzed to evaluate the efficacy of bone repair.
Results: The number of NCs and of colony-forming units within the scaffolds were increased 54.8 times and 53.4
times, respectively, compared with untreated bone marrow. In the BMSC-BM/β-TCP group, CT examination revealed
that the scaffolds were gradually absorbed and the bony defects were restored. Micro-CT and histological
examination confirmed that the implantations led to good repair of the defects, with 6 out 8 orbital defects
completely restored in the experimental group, while by contrast, the grafts in the control groups did not fully
repair the bony defects, a difference which was statistically significant (p < 0.05).
Conclusions: Tissue-engineered bone, constructed using BMSCs isolated by red cell lysis of BM, can restore
critical-sized orbital wall defects in canines.Introduction
Orbital bone defects can occur as a result of facial
trauma, tumor invasion, congenital malformation, or in-
flammatory disease, and often lead to impairment of vis-
ual function and deformity of facial appearance. Such
defects usually arise at the inferior and medial orbital
walls because of their thickness of only 0.3 to 0.9 mm,
and cannot heal spontaneously, since the orbital con-
tents occupy the defect area and herniate into the para-
nasal sinus through the defect. Consequently orbital* Correspondence: fanxq@sh163.net
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reconstruction.
Clinical reconstruction of bone defects has been per-
formed using various materials including titanium, porous
polyethylene, hydroxyapatite, silicone, and bone grafts.
The above artificial materials act as non-absorbable for-
eign bodies and have been associated with infection and
extrusion, as well as cyst formation [1-3]. Although con-
sidered as the ‘gold standard’ for bone defect repair, au-
tologous and allogenous bone grafting is limited by
certain disadvantages, such as donor site morbidity,
pathogen transfer, and long recovery period [4,5]. To over-
come these issues, tissue engineering has proven to be atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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fects [6-11].
Bone tissue engineering combines three key elements:
cells with osteogenic potential, osteoconductive scaf-
folds, and osteoinductive growth factors. The element of
the stem or osteoprogenitor cells is the key point of tis-
sue engineering for bone restoration, as they are even
capable of accomplishing bone regeneration without
scaffolds in vivo [12-14]. Compared with other sources
of stem cells, bone marrow (BM)-derived mesenchymal
stem cells (BMSCs) are the source which has been most
frequently applied both clinically and experimentally for
bone tissue engineering, since BMSCs have a high osteo-
genic capability in vivo and in vitro, and are easy to iso-
late from aspirated bone marrow that is extensively
available. However, BMSCs only comprise approximately
0.001–0.01% of the total population of nucleated cells
(NCs) in the bone marrow, which need to be cultivated
and expanded in vitro for further application. The ex-
pansion process in vitro involved many problems, such
as the time-consuming, high cost, and ethical issues
caused by the addition of animal serum, which remain
an obstacle toward clinical application of BMSCs. Sev-
eral methods for concentration of BMSCs have been in-
troduced for bone tissue engineering in the surgical
environment. Techniques based on density gradient cen-
trifugation for concentration of bone marrow cells need
too much bone marrow (52–252 ml) and special equip-
ment [15-21]. In selective cell retention (SCR) technol-
ogy, marrow is passed through a porous matrix which
utilizes the physical principles of an affinity column to
enrich osteoprogenitor cells that are more prone to at-
tach to the matrix than other NCs, while hematopoietic
cells pass through. However this method requires scaf-
folds in granular form with specific volume (1.5-10 ml),
and there are no standards for SCR devices or bone mar-
row flow rate [22-25]. In addition, both these technolo-
gies have a low concentration rate for BMSCs (<6 times)
leading to a tremendous waste of bone marrow. Isolation
of BMSCs by red blood cell lysis is a faster and more ef-
ficient method than density gradient centrifugation and
has high utilization of bone marrow [26,27], thus it
shows promise in clinical applications for bone tissue
engineering.
In this study, we constructed tissue-engineered bone
using BMSCs obtained by red blood cell lysis of bone
marrow combined with porous β-tricalcium phosphate
(β-TCP), a degradable bioceramic scaffold that has been
extensively used in clinical and experimental bone tissue
engineering [9,15,25,28], and used this to restore medial
orbital wall defects in canines. The overall objectives of
this study were therefore (1) to evaluate the potential of
the constructed tissue-engineered bone; (2) to examine
the increase in the numbers of NCs and BMSCs infusedin the β-TCP; (3) to investigate the effectiveness of this
technique in repairing orbital wall defects.
Materials and methods
Animals
All experimental procedures were performed following
animal protocols approved by the Animal Care and Ex-
periment Committee of Shanghai Jiao Tong University
School of Medicine. Animals were housed in the Animal
Center of Ninth People's Hospital Shanghai Jiao Tong
University School of Medicine. A total of 14 adult beagle
dogs in healthy condition, aged 1-year-old with an aver-
age weight of 14.5 kg were used in this study.
Bone marrow aspiration
After induction of general anesthesia with ketamine (10
mg/kg) and 5% pentobarbital (0.5 ml/kg), 20 ml bone
marrow was collected into a 50 ml centrifuge tube con-
taining 1 ml heparin solution (1000 units/ml) from both
sides of the iliac crest area in 2 ml increments from all
animals. This method was to reduce the degree of dilu-
tion by peripheral blood and obtain the highest quality
bone marrow [29].
Isolation of BMSCs by red blood cell lysis
Each 20 ml heparinized marrow suspension was divided
into 2 equal portions, and each portion was mixed with
30 mL 4°C red blood cell lysis buffer (Qcbio Science &
Technologies Co., Ltd., Shanghai, China) in a 50 ml centri-
fuge tube, and incubated for 10 min at room temperature
on a horizontal shaker. The suspensions were then centri-
fuged at 400 g for 5 min and the supernatant was discarded;
the pellet was then washed twice in phosphate buffered sa-
line (PBS).
Graft preparation
β-TCP scaffolds (Shanghai Bio-Lu Biomaterials Co., Ltd)
were molded into 3-mm-high symmetric cylinders 10
mm in diameter as before [30]. With a resistance to
pressure of 2–4 Mpa at the circular center, the scaffolds
had a volume porosity of 72% with a pore diameter of
450 ± 50 μm, and fully interconnected geometry with
interconnection pore size of 120 ± 50 μm.
A custom-made cell-scaffold combination device was
designed specifically for this study. The device was made
from sterilized ophthalmic plastic adhesive membrane (3L
Medical Product Group Co., Ltd., Jiangxi, China) encapsu-
lating a β-TCP scaffold centrally and two plastic tubes bi-
laterally connected with two 10 ml syringes (Figure 1).
Before assembly, the β-TCP was hydrated with saline for 2
min, and then the saline was removed. An aliquot of 0.1
ml heparinized marrow suspension was mixed with
BMSCs washed by PBS, and then approximately 0.25 ml
of the BMSC-BM suspension was fully introduced into
Figure 1 Illustration of the BMSC/BM and β-TCP combination process using a custom-made stem cell-scaffold combination device.
(A) Conceptual diagram of the combination process. (B) Conceptual diagram of the completed process. (C) Photograph showing the successful
combination of stromal cells with scaffold.
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The BMSC-BM/β-TCP composites were then incubated
at 37°C, under conditions of 5% CO2, 95% O2 and 100%
saturation, for 2 h to allow the cells to attach before im-
plantation, while β-TCP alone was hydrated with 0.25 ml
saline for 2 h under the same incubation conditions before
implantation.
Surgical procedure
The beagles were anesthetized using a combination of
ketamine (10 mg/kg) and 5% sodium pentobarbital (0.5
ml/kg) given subcutaneously. The skin around the
medio-inferior orbital rim was shaved and disinfected. A
crescent-shaped incision was made to access the medial
wall, and subcutaneous tissue, muscle and periosteum
were separated. A full thickness bony defect with a
diameter of 10 mm was created using a 10-mm diameter
trephine, leaving at least 5 mm of the orbital anterior
rim. The periosteum to a distance of 5 mm around the
defect and the nasal sinus mucosal membrane adjacent
to the defect were removed. The wound was irrigated
with copious quantities of saline to remove any remaining
fragments of cancellous bone. Twenty-four medial side or-
bital bone defects in 12 beagles were randomly divided
into four groups: BMSCs-BM/β-TCP composite (n = 8),
BM/β-TCP composite (n = 6), β-TCP alone (n = 6), or
were left untreated (n = 4), and 2 remaining dogs were
used as normal controls (Figure 2A and B). Upon comple-
tion of the procedure, the incisions were carefully closed
in layers with 4–0 nylon. Post-operatively, 0.8 million
units of penicillin were given intramuscularly twice a day
for three days.Enrichment of NCs and BMSCs in the graft
The BMSC-BM suspensions loaded onto the scaffold
were processed by red blood cell lysis then washed twice
in PBS, in a process involving three centrifugation steps
that resulted in cell loss. Knowing the numbers of NCs
and BMSCs in the original BMSC-BM suspensions and
the second PBS suspensions, cell loss could be calculated
after two centrifugation steps, then the numbers of NCs
and BMSCs after three centrifugation steps in the
BMSC-BM suspensions could be deduced, and the fold
concentration of NCs and BMSCs in the graft compared
with the BM could be obtained.
The number of NCs was counted using a hemocytometer
(Beckman Coulter HMX); 0.5 ml of the original hepa-
rinized marrow suspensions and 0.5 mL of the second
PBS suspensions were tested. The number of BMSCs
was determined using an established colony forming
assay [31], in which the number of colony-forming units
(CFUs) expressing alkaline phosphatase was manually
counted. Aliquots of 0.2 ml of the original heparinized
marrow suspensions and 0.2 ml of the second PBS sus-
pensions were directly added into 6-well plate then
mixed with 2 ml α-minimum essential medium (α-MEM,
Gibco, Carlsbad, CA) containing 10% fetal bovine serum
(Hyclone, Logan, UT), 50 μM ascorbic acid, 10 mM β-
glycerophosphate and 10 nM dexamethasone (Sigma, St
Louis, MO), respectively. Cells were cultured at 37°C in a
humidified atmosphere of 5% CO2. The culture medium
was exchanged after 48 h and then every 2 days. On day
10, alkaline phosphatase staining was performed in situ.
Colonies containing 10 or more cells expressing alkaline
phosphatase were counted as osteoprogenitor cells.
Figure 2 Repair the medial wall defect and specimen harvest at 24 weeks post-operatively. (A) 10 mm in diameter defect in the orbital
medial wall. (B) The graft was implanted into the defect. (C) The BMSC-BM/β-TCP group shows bony union achieving around the entire defects.
(D) Gross view of the specimen. (E) The BM/β-TCP group shows new bone formation do not extent to the middle of the grafts, where orbital soft
tissue adhered. (F) The β-TCP group shows grafts are still visible as porous cylinder shapes, with a raised surface.
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At 12 and 24 weeks post-operation under general anesthesia,
canine head CT scanning was performed using multi-
slice spiral CT (GE Lightspeed Ultra 16, Milwaukee, WI),
three-dimensional (3D) images were reconstructed.
Gross observation and micro-CT measurement
All animals were euthanized at 24 weeks postopera-
tively, and the implants and surrounding tissues wereharvested using a saw. Specimens were subjected to
micro-CT (μ80, Scanco Medical, Zurich, Switzerland)
measurement. 3D images were reconstructed, and the
percentage of the defect covered by new bone tissue was
calculated.
Histological analysis
After harvest, the specimens were fixed in 10% formalin
solution and dehydrated through a graded series of
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imens were cut in a longitudinal fashion. The sections
were then surface-stained with Van Gieson’s picro-fuchsin
for histomorphometric analysis as before [32]. The surface
areas of the newly-formed bone (stained red) and the TCP
residue (stained black) were measured using Image Pro
Plus™ (Media Cybernetics, Silver Springs, MD).Statistical analysis
All data are presented as the mean ± SD. Using the soft-
ware SPSS 17.0 (SPSS Inc., Chicago, IL), Fisher’s exact
test was used to detect differences between groups with
the level of significance set at P < 0.05.Results
All animals maintained normal daily activities and remained
in healthy condition post-operation. There were no cases of
hemorrhage or infection around the incisions, and swelling
disappeared within 2 weeks postoperatively.Enrichment of NCs and BMSCs
The mean number of NCs in the marrow samples was
(13.3 ± 9.0) × 106/ml, with BMSCs present at (128.6 ±
51.1)/ml. After two centrifugation steps, the numbers of
NCs and BMSCs were (9.9 ± 7.0) × 106/ml and (93.1 ±
36.9)/ml respectively. The loss rates of NCs and BMSCs
per centrifugation step [(14.68 ± 0.03) % and (14.70 ±
0.02)%] were calculated, and the numbers of NCs and
BMSCs after the third centrifugation step were (169.3 ±
123.2) × 106 and (1585.6 ± 631.8), which were also the
counts of NCs and BMSCs combined in the grafts.
Compared with a BM graft, the BMSC-BM graft con-
tained on average 54.8 times more NCs and 53.4 times
more BMSCs (Table 1).Spiral CT scanning
Twelve weeks after implantation, the edges of the
BMSC-BM/β-TCP composites appeared faint, and cor-
tical bone replaced the grafts. BM/β-TCP and β-TCP
grafts retained their original shape, and little cortical
bone could be seen ingrown at the periphery. Twenty-
four weeks after surgery, in the BMSC-BM/β-TCP
group, graft thickness was identical to that of a normal
orbit, and grafts were replaced by new cortical bone,
which had assumed the contour of a normal orbit. In
the BM/β-TCP group, ossifications had developed
around the rim of the implant, but the shape of the graft
was still identifiable. There was no obvious new bone
formation around grafts in the β-TCP group, and con-
tour changes of the graft were minimal. In the untreated
group, no callus formation was observed during the en-
tire post-operative period (Figure 3).Gross view
After harvesting the specimens, the BMSC-BM/β-TCP
group showed new bone formation filling the defects,
with bony union being achieved all around the defects,
and the surface of the new bone level with adjacent bone
and appearing whitish in color (Figure 2C and D). In the
BM/β-TCP group, new bone formation was observed
around the defects, but this did not extend to the middle
of the grafts, where orbital soft tissue adhered (Fig-
ure 2E). In the β-TCP group, grafts were still visible as
porous cylinder shapes, with a raised surface compared
to that of the adjacent orbit (Figure 2F).
Micro-CT measurement
Micro-CT images were taken at 24 weeks post-operation
(Figure 4). New bone regeneration across the diameter
of the defects occurred in 6 out of 8 BMSC-BM/β-TCP
composites, with > 90% of the defect filled with newly-
formed bone tissue and smoothly remodeled bone con-
tours. The new bone and the bony defect were con-
nected by a synostosis, with an indistinct boundary, and
a few residual β-TCP particles were scattered among the
newly formed bone in transection view. Only one of the
BM/β-TCP composites exhibited new bone regeneration
extending the total length of the defect, but all grafts re-
stored < 50% of the defect. In transection plane, new
bone formation was observed peripherally, but the cen-
ter of the scaffolds was completely degraded. In the TCP
group, bone union occurred here and there around the
defect, the non-degraded scaffold retained its original
shape, and only a small amount of new bone was formed
under the non-degraded scaffold. In the untreated group,
fibrous tissue and mucosal membrane occupied the de-
fects, no obvious new bone formation was detected.
Histological analysis
Histology of hard tissue sections using Stevenel’s blue/
Van Gieson’s picro-fuchsin staining at 24 weeks post-
operation was performed (Figure 5). Newly-formed bone
tissue was stained red and had a woven, trabecular ap-
pearance with complete bone union in BMSC-BM/β-
TCP grafts, which differed from the lamellar bones of
the normal group. In the BM/β-TCP group, the new
bone was intermittent, porous and thin. There was no
obvious bone union, only a small amount of new bone
formation, and much scaffold remaining in the TCP
group. In the untreated group, only a trivial amount of
new bone was formed at the interface between the or-
bital contents and the sinus membrane. The percentage
of new bone area in the BMSC-BM/β-TCP group (62.57
± 7.40%) was obviously and significantly greater than
that in the control groups (38.37 ± 4.27% in the BM/β-
TCP group; 22.39 ± 2.56% in the β-TCP group; and
14.23 ± 1.85% in the untreated group; p < 0.05). Less β-
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Figure 3 Three-dimensional CT image analysis of the repaired orbital bone defects in the various group at 12 and 24 weeks. (A1-2) In
the BMSC-BM/β-TCP group, the graft gradually absorbed and accompanied with new bone formation that is identical to normal orbits. (B1-2) In
the BM/β-TCP group, the graft absorbed with less bone regeneration. (C1-2) In the β-TCP group, the scaffold remained original shape. (D1-2) No
obvious new bone formation in the blank group.
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(9.36 ± 3.12%) compared to the other groups (15.33 ±
1.61%, in the BM/β-TCP group; 34.92 ± 4.09% in the β-
TCP group; p < 0.05).
Discussion
Various strategies of enriching stem/progenitor cells for
use in cell-based bone regeneration without expansion
in vitro have been explored both clinically and experi-Figure 4 Micro-CT imaging analysis at 24 weeks post-operatively. The
eye ball and the images of section view.mentally with varying degrees of success. Connolly demon-
strated that bone marrow concentrated by unit gravity
sedimentation or centrifugation could significantly increase
deposition of calcium in ectopic sites of the rabbit, which
allowed four to five times as many NCs to be implanted
[33]. A cell separator based on differences in cell density in
bone marrow, used the centrifugation method to concen-
trate progenitor cells and mononuclear cells, and has been
applied in several clinical studies of bone regenerationtop and bottom panels represent the 3D-images from the face to the
Figure 5 Van Gieson’s picro-fuchsin staining of the samples for histological analysis of new bone formation and β-TCP residue at 24
weeks post-operatively. (A) From top to bottom: BMSC-BM/β-TCP, BM/β-TCP, β-TCP and blank group (original magnification 10× and 40×).
New bone appears red, and β-TCP appears black. (B, C) There were significant differences between the BMSC-BM/β-TCP group and control
groups in the new bone area and β-TCP residue (*p < 0.05, **p < 0.01).
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tive correlation between new bone regeneration and the
number and concentration of osteoprogenitors in the bone
marrow graft. Use of the cell separator reduced 150 ml and
300 ml of bone marrow to 30 ml and 50 ml of mono-
nuclear cell suspension and concentrated the BMSCs
(CFU-F) approximately 4.3 and 4.2 times, respectively
[13,14,19]. In a study, good results were achieved in 95.1%
of cases of posterior spinal fusion with grafts constructed of
β-TCP and bone marrow stem cells enriched by the separ-
ator, which reduced 252 ml of marrow to 45 ml of enriched
stem cell suspension and concentrated the BMSCs 4.3
times [15]. Recently, bone marrow mononuclear cellsconcentrated by a novel point-of-care bone marrow aspir-
ate concentrate (BMAC) system, which relies on density
gradient centrifugation, was shown to enhance bone regen-
eration and healing in vivo [16-18,20,21]. In comparison
with the Ficoll isolation procedure, the BMAC method
yielded a 2.4-fold higher total number of nucleated cells
and a similar number of BMSCs [17,21].
The selective cell retention method that is based on
BMSCs property of adhesion to a matrix was used to con-
struct graft materials with enriched osteoprogenitor cells.
BMSCs could be enriched 3.4-5.6 times by SCR method
and were more likely to be retained in demineralized can-
cellous bone matrix than other bone marrow-derived cells,
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using SCR technology combined with demineralized bone
and cancellous chips to repair canine critical-size femoral
defects and obtained the same effect as with autologous
bone. In their study the osteoprogenitor cells were con-
centrated 3.6 times and the nucleated cells 1.4 times [23].
This enrichment method to achieve a maximum of 3
times more BMSCs which they combined with β-TCP to
achieve similar fusion rates with autografts in an ovine
spine fusion model [25].
Although these methods generated the expected re-
sults in new bone regeneration, they are not applic-
able to the repair of orbital wall bone defects. The
orbital wall is so thin and lacking in support that it
requires thin and rigid scaffolds that possess rather a
small volume in total to repair, and as a result the
volume of BM needed for the centrifugation method
is too large and would result in a great deal of waste,
while using SCR enrichment technology for such
regular and thin scaffolds is difficult and inefficient.
In addition, the specific and expensive equipment
needed for the centrifugation technique, and the lack
of any standard for the SCR device or the bone mar-
row flow rate has limited their further application.
The red cell lysis method for isolation of BMSCs
from BM has proven that it is efficient, faster and
more easily standardized for clinical applications of
BMSCs [26,27], although, it has never previously
been used for tissue-engineered bone reconstruction.
Based on the above findings, we used the red cell
lysis method to collect NCs from BM and combine
them with β-TCP and BM to restore medial orbital
wall defects in a canine model in this study.
Lysis with ammonium chloride depends on the
continuous flow of NH3 and CO2 through the cell
membrane into erythrocytes, which contain large
quantities of carbonic anhydrase that converts NH3
to NH4
+ and CO2 to HCO3
−. This lysis procedure has
a great effect on red blood cells but very few toxic
effects on NCs in the BM, such as BMSCs, osteo-
cytes, endothelial cells, reticular cells, or fibroblasts
as well as platelets. All these components in 20 ml
BM were collected after centrifugation three times
and used to construct tissue-engineered bone, which
contained 169.3 × 106 BMSCs and 1585.6 NCs. Due
to the thin scaffold used in our study, the total vol-
ume of the scaffold was very small and less than 0.25
ml, so that NCs were concentrated 54.8 times and
BMSCs, 53.4 times. The concentration rates of NCs
and BMSCs were quite close and different from
those of the SCR method that had a higher concen-
tration rate of BMSCs. In spite of that, the concen-
tration rates of both NCs and BMSCs in our study
were much higher, being at least 10 times morecompared to those obtained using centrifugation and
SCR methods.
The optimal density of stem cells infused in a scaffold is
as yet unknown. It could be affected by scaffold properties,
sites of transplantation, growth factors and especially cell
conditions, including cultivation and expansion in vitro,
genetic modification, and direct harvest. There are large
variations in cell quantities infused into scaffolds when
stem cells are expanded in vitro or directly concentrated.
Zhou [9] and Yuan [28] both transplanted culture-
expanded BMSCs with a concentration of 20 × 106 /ml
into β-TCP and obtained expected results. Haynesworth
considered that the optimal concentration of stem cells in-
fused into scaffolds would range from 0.7 to 20 × 106/ml
[34]. Consequently, numbers of culture-expanded stem
cells may be thousands of times higher than those ob-
tained by concentration methods or the SCR method of
harvest, and hundreds of times higher than those obtained
by the red cell lysis method used herein, that would be the
closest to the culture-expanded group among the above
non-culture methods. In view of the results of previous in-
vestigations of orbital bone defects restored using tissue
engineering techniques, grafts combined with BM [6],
nanocomposites [8] or bone morphogenetic protein-2
(BMP-2) [7] with different kinds of scaffolds, did not lead
to complete restoration of orbital bone defects. Hence,
since the incorporation of more BMSCs or osteoprogenitor
cells could be more beneficial to orbital bone regeneration,
we concentrated and combined the highest concentration
of BMSCs achieved so far under intro-operative conditions,
and succeeded in achieving almost complete repair of the
orbital bony defects.
Since it was believed that native BMSCs and β-
TCP alone would not be enough to regenerate new
orbital bone, a small amount of BM (0.1 ml) was
added into the grafts, which provided platelets and
plasma to reproduce the native bone marrow envir-
onment. In addition, a considerable number of plate-
lets remained in the pellet after red cell lysis, which
could release platelet-derived growth factor (PDGF)
that both contributes to osteoblast differentiation and
helps to stabilize newly-forming vessels, and has been
deemed to be a powerful agent for new bone forma-
tion [35]. In the experimental group newly-formed
orbital bone was also remodeled in response to the
orbital stresses at the transplantation site, which
comprised the outward pressure of orbital contents
and inward pressure of nasal sinus. The orbital con-
tents that mainly consists of eyeball and orbital fat,
but paranasal sinus is a bony cavity, the outward
pressure is prominent, which made newly-formed or-
bital bone slightly curved to nasal cavity. As a result,
the newly-formed orbital bone exhibited similar bony
contour and structures to normal orbital bone.
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In conclusion, The BMSC-BM/β-TCP composites were
able to efficiently restore the orbital bone defects, and the
macro- and micro-structure of the newly formed bone
was quite similar to normal orbital bone, also the degrad-
ation of β-TCP scaffold is consistency with the new bone
formation. This study revealed that tissue-engineered
bone can be constructed using the red cell lysis method
under intraoperative conditions. BMSCs and NCs infused
into scaffolds were more highly concentrated than by any
other method due to the thin structure of the orbital wall
and the red cell lysis method used herein, which provided
an excellent model for intraoperative bone tissue engin-
eering research.
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